The Effect of Fulvic Acid on Alzheimer's Disease - A Systematic Review
DOI:
https://doi.org/10.12775/QS.2025.41.60196Keywords
fulvic acid, neurodegenerative diseases, Alzheimer's disease, shilajit, nutraceuticalsAbstract
Introduction and aim of the study: Neurodegenerative diseases, including Alzheimer's disease, represent a significant health challenge. Therapies are being sought that could delay the development of these diseases and also mitigate their course. Fulvic acid, which is an organic humic compound with antioxidant and anti-inflammatory properties, has attracted increasing interest in the context of treating neurodegenerative diseases. Our study aims to evaluate the effects of fulvic acid on neurodegenerative diseases, mainly Alzheimer's disease, and to determine its therapeutic potential.
Materials and methods: The paper is based on an analysis of studies available in databases such as PubMed, Google Scholar, ResearchGate, and other scientific databases. Clinical trials, preclinical studies, and review papers on the use of fulvic acid in the context of Alzheimer's disease were searched.
Conclusions: Fulvic acid, due to its anti-inflammatory and neuroprotective abilities, shows promising potential in the treatment of Alzheimer's disease, especially in terms of slowing down the loss of cognitive function and protecting against neurodegeneration. It is advisable to conduct further studies aimed at a more thorough evaluation of the efficacy and safety of fulvic acid in the context of the treatment of Alzheimer's disease and other neurodegenerative diseases.
References
Gałecki W., Szulc A. Psychiatria. Wrocław: Edra Urban & Partner; 2018.
Marcourakis T, Camarini R, Kawamoto EM, Scorsi LR, Scavone C. Peripheral biomarkers of oxidative stress in aging and Alzheimer's disease. Dement Neuropsychol. 2008;2(1):2-8. doi:10.1590/S1980-57642009DN20100002
Xie L, Zhu Q, Lu J. Can We Use Ginkgo biloba Extract to Treat Alzheimer's Disease? Lessons from Preclinical and Clinical Studies. Cells. 2022;11(3):479. Published 2022 Jan 29. doi:10.3390/cells11030479
Liao Z, Cheng L, Li X, Zhang M, Wang S, Huo R. Meta-analysis of Ginkgo biloba Preparation for the Treatment of Alzheimer's Disease. Clin Neuropharmacol. 2020;43(4):93-99. doi:10.1097/WNF.0000000000000394
Nowak A, Kojder K, Zielonka-Brzezicka J, et al. The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer's Disease. Front Pharmacol. 2021;12:775034. Published 2021 Nov 4. doi:10.3389/fphar.2021.775034
Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics. 2019;16(3):666-674. doi:10.1007/s13311-019-00767-8
Gregory J, Vengalasetti YV, Bredesen DE, Rao RV. Neuroprotective Herbs for the Management of Alzheimer's Disease. Biomolecules. 2021;11(4):543. Published 2021 Apr 8. doi:10.3390/biom11040543
Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review. Nutr Neurosci. 2018;21(8):529-538. doi:10.1080/1028415X.2017.1321813
Chen H, Liu S, Ge B, et al. Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial. J Prev Alzheimers Dis. 2021;8(3):249-256. doi:10.14283/jpad.2021.22
Chen H, Liu S, Ji L, et al. Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial. Mediators Inflamm. 2016;2016:5912146. doi:10.1155/2016/5912146
Wang L, Zhou C, Yu H, et al. Vitamin D, Folic Acid and Vitamin B12 Can Reverse Vitamin D Deficiency-Induced Learning and Memory Impairment by Altering 27-Hydroxycholesterol and S-Adenosylmethionine. Nutrients. 2022;15(1):132. Published 2022 Dec 27. doi:10.3390/nu15010132
Alghamdi M, Braidy N. Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach. J Alzheimers Dis. 2024;101(s1):S467-S477. doi:10.3233/JAD-231277
Long AN, Owens K, Schlappal AE, Kristian T, Fishman PS, Schuh RA. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model. BMC Neurol. 2015;15:19. Published 2015 Mar 1. doi:10.1186/s12883-015-0272-x
Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK. Shilajit: a review. Phytother Res. 2007;21(5):401-405. doi:10.1002/ptr.2100
Carrasco-Gallardo C, Guzmán L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012;2012:674142. doi:10.1155/2012/674142
Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455-532. doi:10.1016/S1474-4422(16)00062-4
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005
Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-128. doi:10.31887/DCNS.2009.11.2/cqiu
Ballesteros S, Nilsson L-G, Lemaire P (2009) Ageing, cognition, and neuroscience: an introduction. European Journal of Cognitive Psychology, 21:2,161–175
Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci. 2004;5(2):87-96. doi:10.1038/nrn1323
Juan SMA, Adlard PA. Ageing and Cognition. Subcell Biochem. 2019;91:107-122. doi:10.1007/978-981-13-3681-2_5
Celsis P. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?. Ann Med. 2000;32(1):6-14. doi:10.3109/07853890008995904
Carrasco-Gallardo C, Farías GA, Fuentes P, Crespo F, Maccioni RB. Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins. Arch Med Res. 2012;43(8):699-704. doi:10.1016/j.arcmed.2012.10.010
Cornejo A, Jiménez JM, Caballero L, Melo F, Maccioni RB. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease. J Alzheimers Dis. 2011;27(1):143-153. doi:10.3233/JAD-2011-110623
Farías G, Pérez P, Slachevsky A, Maccioni RB. Platelet Tau Pattern Correlates with Cognitive Status in Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2012;31(1):65-69. doi:10.3233/JAD-2012-120304
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590. doi:10.1016/S0140-6736(20)32205-4
Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014;8:112. Published 2014 Apr 22. doi:10.3389/fncel.2014.00112
Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a Common Feature of Neurodegenerative Disorders. Front Pharmacol. 2019;10:1008. Published 2019 Sep 12. doi:10.3389/fphar.2019.01008
Carrasco-Gallardo C, Guzmán L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012;2012:674142. doi:10.1155/2012/674142
Jomehpour D, Sheikhlary S, Heydari E, Ara MHM. Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations. IEEE Trans Nanobioscience. 2024;23(1):3-10. doi:10.1109/TNB.2023.3267268
Ghosal S, Lal J, Jaiswal A, Bhattacharya S. Effects of Shilajit and its active constituents on learning and memory in rats. Phytother Res 1993;7(1):29−3
Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020;25(24):5789. Published 2020 Dec 8. doi:10.3390/molecules25245789)
Passeri E, Elkhoury K, Morsink M, et al. Alzheimer's Disease: Treatment Strategies and Their Limitations. Int J Mol Sci. 2022;23(22):13954. Published 2022 Nov 12. doi:10.3390/ijms232213954)
Briggs R, Kennelly SP, O'Neill D. Drug treatments in Alzheimer's disease. Clin Med (Lond). 2016;16(3):247-253. doi:10.7861/clinmedicine.16-3-247
Birks, J., & Harvey, R. (2003). Donepezil for dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd001190
Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341. doi:10.1056/NEJMoa013128
Dominguez-Meijide A, Vasili E, König A, et al. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization. Sci Rep. 2020;10(1):12827. Published 2020 Jul 30. doi:10.1038/s41598-020-69744-y
Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014;8:112. Published 2014 Apr 22. doi:10.3389/fncel.2014.00112
Rybakowski J. Psychofarmakologia kliniczna. Warszawa: PZWL Wydawnictwo Lekarskie;; 2023
Dai C, Xiao X, Yuan Y, Sharma G, Tang S. A Comprehensive Toxicological Assessment of Fulvic Acid. Evid Based Complement Alternat Med. 2020;2020:8899244. Published 2020 Dec 16. doi:10.1155/2020/8899244
Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y. The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review. J Alzheimers Dis. 2022;85(3):1195-1204. doi:10.3233/JAD-215423
Morris R, Luboff H, Jose RP, et al. Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System. J Alzheimers Dis. 2021;81(1):297-307. doi:10.3233/JAD-201551
Tanaka A, Koga S, Hiramatsu Y. Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. Intern Med. 2009;48(14):1219-1223. doi:10.2169/internalmedicine.48.2181
Román GC, Rogers SJ. Donepezil: a clinical review of current and emerging indications. Expert Opin Pharmacother. 2004;5(1):161-180. doi:10.1517/14656566.5.1.161
Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015;9(9):CD001191. Published 2015 Sep 22. doi:10.1002/14651858.CD001191.pub4
Patel PH, Gupta V. Rivastigmine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 17, 2023.
Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-S22. doi:10.1212/01.wnl.0000281847.17519.e0
Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;2006(1):CD001747. Published 2006 Jan 25. doi:10.1002/14651858.CD001747.pub3
Magierski R, Sobow T. Benefits and risks of add-on therapies for Alzheimer's disease. Neurodegener Dis Manag. 2015;5(5):445-462. doi:10.2217/nmt.15.39
Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003;9(3):275-308. doi:10.1111/j.1527-3458.2003.tb00254.x
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022;9(2):197-210. doi:10.14283/jpad.2022.30
van Rensburg CE. The Antiinflammatory Properties of Humic Substances: A Mini Review. Phytother Res. 2015;29(6):791-795. doi:10.1002/ptr.5319
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kornelia Kaźmierkiewicz, Martyna Chojnacka, Marta Ewelina Lis, Ewa Ciechańska, Kornel Kapuśniak, Weronika Suszczyńska, Katarzyna Rumianek-Fidziukiewicz, Zuzanna Lasota
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 108
Number of citations: 0
